drugset / Trial / NCT02451865

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

NCT02451865

NaSingle-groupOpen-labelTreatment

Summary

This phase Ib trial studies the safety and best dose of binimetinib when given in combination with docetaxel in treating patients with previously treated, stage IV non-small cell lung cancer. Binimetinib and docetaxel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2016-06
Primary completion
2018-06
Completion
2019-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Binimetinib Small molecule Oral
Background Docetaxel Small molecule 75 mg/m2 Intravenous